Conditions: Metabolism and Nutrition Disorder Obesity
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 846
Healthy volunteers: no

Brief summary:
This trial is conducted in Africa, Asia, Europe and the United States of America (USA).

The aim of this trial is to investigate the potential of liraglutide to induce and maintain weight loss in overweight or obese subjects with type 2 diabetes. Treatment will be added onto subject's pre-trial background diabetes treatment of either diet and exercise only or single compound oral antidiabetic drug (OAD) treatment (metformin, sulphonylurea \[SU\] or glitazone) or combination OAD treatment (metformin, sulphonylurea or glitazone). The duration of the trial will be 56 weeks followed by a 12 week observational follow-up period.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: liraglutide intervention 2: liraglutide intervention 3: placebo
Intervention descriptions: intervention 1: Liraglutide 3.0 mg for subcutaneous (under the skin) injection once daily for 56 weeks. intervention 2: Liraglutide 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks. intervention 3: Liraglutide placebo of either 3.0 mg or 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.

Protocol document: